Clinical trial
Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients
NCT04961658 is registered in ClinicalTrials.gov with Northern Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients
- Lead sponsor
- Northern Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 11, 2021
- Completion date
- January 8, 2024
- Enrollment
- 11 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
septic shock